NZ593027A - Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan - Google Patents

Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan

Info

Publication number
NZ593027A
NZ593027A NZ593027A NZ59302709A NZ593027A NZ 593027 A NZ593027 A NZ 593027A NZ 593027 A NZ593027 A NZ 593027A NZ 59302709 A NZ59302709 A NZ 59302709A NZ 593027 A NZ593027 A NZ 593027A
Authority
NZ
New Zealand
Prior art keywords
melphalan
containing antibodies
antibodies recognizing
combinations containing
recognizing specifically
Prior art date
Application number
NZ593027A
Other languages
English (en)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40578382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ593027(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NZ593027A publication Critical patent/NZ593027A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ593027A 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan NZ593027A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08291116A EP2191840A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
PCT/IB2009/055389 WO2010061357A1 (en) 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan

Publications (1)

Publication Number Publication Date
NZ593027A true NZ593027A (en) 2012-12-21

Family

ID=40578382

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ593027A NZ593027A (en) 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan

Country Status (32)

Country Link
US (1) US9259406B2 (enExample)
EP (2) EP2191840A1 (enExample)
JP (3) JP2012510461A (enExample)
KR (1) KR101733252B1 (enExample)
CN (1) CN102264385B (enExample)
AR (1) AR074219A1 (enExample)
AU (1) AU2009321249B2 (enExample)
BR (1) BRPI0921864B1 (enExample)
CA (1) CA2744990C (enExample)
CL (1) CL2011001254A1 (enExample)
CO (1) CO6440557A2 (enExample)
CR (1) CR20110280A (enExample)
EA (1) EA026867B1 (enExample)
EC (1) ECSP11011062A (enExample)
HN (1) HN2011001417A (enExample)
IL (1) IL213116B (enExample)
MA (1) MA32896B1 (enExample)
ME (1) ME01136B (enExample)
MX (1) MX342625B (enExample)
MY (1) MY164577A (enExample)
NI (1) NI201100105A (enExample)
NZ (1) NZ593027A (enExample)
PA (1) PA8850101A1 (enExample)
PE (1) PE20120340A1 (enExample)
SG (1) SG171820A1 (enExample)
SV (1) SV2011003924A (enExample)
TN (1) TN2011000232A1 (enExample)
TW (1) TWI454260B (enExample)
UA (1) UA107069C2 (enExample)
UY (1) UY32263A (enExample)
WO (1) WO2010061357A1 (enExample)
ZA (1) ZA201103925B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0816777B2 (ja) 1988-10-13 1996-02-21 富士写真フイルム株式会社 画像形成方法
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
WO2011130624A2 (en) * 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT2621531T (pt) 2010-09-27 2017-03-13 Morphosys Ag Anticorpo anti-cd38 e lenalidomida ou bortezomibe para o tratamento de mieloma múltiplo e linfoma não-hodgkins
EP2622064B1 (en) 2010-10-01 2019-05-29 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
HRP20171964T1 (hr) * 2012-09-25 2018-02-23 Morphosys Ag Kombinacije i njihova upotreba
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EA035098B1 (ru) * 2014-07-31 2020-04-27 Санофи Способ лечения рецидивирующей и/или рефрактерной множественной миеломы
WO2016022589A2 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
JP6707531B2 (ja) 2014-09-09 2020-06-10 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体による併用療法
TWI721959B (zh) 2014-12-04 2021-03-21 美商健生生物科技公司 治療急性骨髓性白血病之抗ｃｄ３８抗體
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
NZ777133A (en) 2015-06-22 2025-05-02 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SMT202100192T1 (it) 2015-11-03 2021-05-07 Janssen Biotech Inc Formulazioni sottocutanee di anticorpi anti-cd38 e loro usi.
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN109689690B (zh) 2016-07-15 2023-10-03 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
AU2018359527A1 (en) 2017-10-31 2020-05-07 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
WO2019130228A1 (en) * 2018-01-01 2019-07-04 Orbicular Pharmaceutical Technologies Pvt. Ltd., Stable liquid compositions of melphalan
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
KR20210068485A (ko) 2018-09-28 2021-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 노화를 역전시키고 기관 및 조직 재생을 촉진시키기 위한 세포 재프로그래밍
US20220144965A1 (en) 2019-03-15 2022-05-12 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
BR112022010905A2 (pt) 2019-12-05 2022-09-06 Sanofi Aventis Us Llc Formulações de anticorpos anti-cd38 para administração subcutânea
US20240109977A1 (en) 2021-01-14 2024-04-04 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US7227002B1 (en) 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999062526A2 (en) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
GB0221574D0 (en) 2002-09-17 2002-10-23 Isis Innovation Treatments
NZ548990A (en) 2004-02-06 2009-06-26 Morphosys Ag Anti-CD38 human antibodies and uses therefor
NZ561883A (en) * 2005-03-23 2010-11-26 Genmab As Antibodies against CD38 for treatment of multiple myeloma
HUE044136T2 (hu) 2006-09-26 2019-09-30 Genmab As Anti-CD38 plusz kortikoszteroidok plusz nem-kortikoszteroid kemoterápiás szer daganatok kezelésére
US20080092384A1 (en) * 2006-10-16 2008-04-24 Schaake Mark D Installation of Middle Bearing for a Crankshaft
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide

Also Published As

Publication number Publication date
CO6440557A2 (es) 2012-05-15
EA026867B1 (ru) 2017-05-31
KR20110096550A (ko) 2011-08-30
NI201100105A (es) 2011-12-13
MX342625B (es) 2016-10-06
HK1164165A1 (en) 2012-09-21
JP2017141233A (ja) 2017-08-17
EA201100864A1 (ru) 2011-12-30
UA107069C2 (uk) 2014-11-25
PA8850101A1 (es) 2010-07-27
UY32263A (es) 2010-06-30
IL213116A0 (en) 2011-07-31
CA2744990A1 (en) 2010-06-03
KR101733252B1 (ko) 2017-05-08
AU2009321249B2 (en) 2016-06-09
JP2012510461A (ja) 2012-05-10
MA32896B1 (fr) 2011-12-01
SV2011003924A (es) 2011-10-07
JP2015205890A (ja) 2015-11-19
CR20110280A (es) 2011-09-20
BRPI0921864A2 (pt) 2018-10-09
EP2191840A1 (en) 2010-06-02
HN2011001417A (es) 2014-01-13
JP6148696B2 (ja) 2017-06-14
MX2011005670A (es) 2011-09-30
PE20120340A1 (es) 2012-04-17
ME01136B (me) 2013-03-20
TN2011000232A1 (en) 2012-12-17
WO2010061357A1 (en) 2010-06-03
ECSP11011062A (es) 2011-07-29
AR074219A1 (es) 2010-12-29
CL2011001254A1 (es) 2012-01-27
ZA201103925B (en) 2012-09-26
SG171820A1 (en) 2011-07-28
AU2009321249A1 (en) 2010-06-03
CN102264385A (zh) 2011-11-30
US20110274686A1 (en) 2011-11-10
US9259406B2 (en) 2016-02-16
TW201023855A (en) 2010-07-01
MY164577A (en) 2018-01-15
CA2744990C (en) 2019-05-07
IL213116B (en) 2018-11-29
TWI454260B (zh) 2014-10-01
EP2370094A1 (en) 2011-10-05
CN102264385B (zh) 2015-05-20
BRPI0921864B1 (pt) 2022-11-16

Similar Documents

Publication Publication Date Title
NZ593027A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
NZ593085A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
NZ592992A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine
NZ593147A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide
MX2021014888A (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda.
UA101487C2 (en) Humanized b-ly1 antibody formulation
MX2012002458A (es) Anticuerpos anti-cdcp1 humanizados.
JP2012510461A5 (enExample)
MX2011012136A (es) Anticuerpo anti-axl.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
TN2013000245A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
EP4282428A3 (en) Anti-cldn6 antibody
GEP20135903B (en) Method of (1s, 2r)-milnacipran synthesis
WO2011133819A3 (en) Methods of enhancing antibody-dependent cellular cytotoxicity
EA201171133A1 (ru) Гуманизированные антитела с противоопухолевой активностью
MY190881A (en) Gas separation modules
TH126243A (th) สารรวมต้านเนื้องอกที่มีแอนติบอดีซึ่งจดจำ cd38 อย่างจำเพาะและไซโคลฟอสฟาไมด์
TN2011000153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide
TH147134A (th) สารรวมต้านเนื้องอกที่มีแอนติบอดีที่จดจำ cd38 อย่างจำเพาะและบอร์ทีโซมิบ

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 NOV 2016 BY CPA GLOBAL

Effective date: 20131010

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2017 BY CPA GLOBAL

Effective date: 20161014

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2018 BY CPA GLOBAL

Effective date: 20171012

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2019 BY CPA GLOBAL

Effective date: 20181011

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2020 BY CPA GLOBAL

Effective date: 20191010

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2021 BY CPA GLOBAL

Effective date: 20201015

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2022 BY CPA GLOBAL

Effective date: 20211014

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2023 BY CPA GLOBAL

Effective date: 20221015

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2024 BY CPA GLOBAL

Effective date: 20231013

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241011

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 NOV 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20251018